Toetal Solutions Raises $1.02 Million in New Financing

Toetal Solutions, Inc., a foot and ankle medical device company pioneering effective solutions for foot and ankle deformities, announced it has closed $1.02M in its initial round of financing, from Runway Healthcare, LP, a medical device accelerator.

Toetal Solutions notes that the proceeds from the funding will enable Toetal to rapidly scale the development of its flagship product, the Ziptoe™ Hammertoe System.

The Ziptoe™ Hammertoe System is designed to enable foot and ankle surgeons to address rigid hammertoe deformities with a simple, easy-to-use implant. The Ziptoe system features a proprietary deployable nitinol implant that comes sterile packed with all necessary disposable instrumentation to perform the procedure in any surgical setting.

“We’ve designed a product with physician input throughout every step of development. Our market research made it clear that the current product offerings for hammertoe fusion lacked efficacy or were too cumbersome to implant easily. Ziptoe’s design meets the core tenants of proper bone fusion: Active Compression, Complete Stability, and Zero Rotation. We are excited to enter this next phase of product development and get this simple and easy-to-use product in the hands of foot and ankle surgeons,” said Jeff O’Donnell, Jr., CEO, and Co-Founder of Toetal Solutions.

Dr. Steven S. Soondar, D.P.M. stated, “The Ziptoe is needed to allow foot and ankle surgeons a reproducible means to correct hammertoe deformities, creating compression across the fusion site while also allowing for easy revision if necessary.”

Runway Healthcare, LP solely funded this financing and has a majority ownership position in the company. Toetal Solutions is Runway Healthcare’s second portfolio company.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.
Vicarious Surgical added Philip Liang and Ric Fulop to their Board of Directors. 

By using this website you agree to accept Medical Device News Magazine Privacy Policy